Continued therapeutic response monitoring in optimal responders with CML

Clinical Advances in Hematology and Oncology

Volumn 10, Issue 12, 2012, Pages 819-821

  Branford, Susan ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PONATINIB;

ARTICLE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; GENE MUTATION; GENE SEQUENCE; HUMAN; MINIMAL RESIDUAL DISEASE; MONITORING; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TREATMENT RESPONSE;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84878062578     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041-6051.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2.2012. http://www.nccn. org/professionals/physician_gls/pdf/cml.pdf. Updated July 22, 2011. Accessed November 26, 2012.
3. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758-3765.